Which Healthcare ETF Is the Better Buy: Vanguard's VHT or Fidelity's FHLC? One basis point separates these two healthcare funds. Here is why the bigger decision is whether to own healthcare at all.
iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026? VanEck's concentrated biotech portfolio surged 30.8% in one year but endured a 39.9% drawdown. iShares offers steadier global healthcare exposure with a 1.5% dividend yield.
There's A Hidden Gem In Eli Lilly's Weight-Loss News — And It Could Slam Compounders Eli Lilly said Thursday it will delay filing for FDA approval of its next-gen weight-loss drug, retatrutide, until the first quarter.
Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know. Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline.
Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT? FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.
Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB? IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% dividend yield.
Concentrated Pharma Exposure or Broader Global Healthcare? PPH vs. IXJ The VanEck Pharmaceutical ETF (PPH) gives investors a concentrated way to own major drugmakers, while the iShares Global Healthcare ETF (IXJ) spreads exposure across the wider healthcare sector. The choice comes down to whether to lean into pharma-driven returns or take a broader approach to global healthcare.
Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF? IHE delivered stronger 5-year returns, but VHT's 0.09% expense ratio and 411 holdings offer broader diversification at lower cost.
Is the iShares Healthcare ETF or the Invesco Nasdaq Biotech ETF the Better Bet for Investors in 2026? One offers global diversification and higher income; the other delivers focused biotech exposure with lower costs and stronger recent gains.
As Healthcare Rallies Is the Vanguard Health Care ETF of the Invesco Pharmaceuticals ETF the Better Fund for 2026? PJP surged 45% in one year, but VHT's lower costs and higher dividend yield appeal to long-term income investors seeking broad sector exposure.
Want Income for Life? Here Are 3 Stocks to Buy Now and Never Sell. A strong yield and an impressive track record of dividend growth aren't enough. The underlying business needs to be enduring.
Insider Moves Are Sending Mixed Signals Across the Tech Sector Broadcom sees insider selling after volatile 2026 trading, while Netskope draws heavy insider buying post-earnings drop and Eli Lilly CEO David Ricks purchases Adobe shares.
PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors? PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield.
Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT? One fund owns the giants of global healthcare, while the other bets on 30 smaller biotech companies.
IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy? IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return.
Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing Novo Nordisk is offering an attractive 3.5% yield backed by a business where volume is the new focus.
Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Weight Loss Drug Advertising Novo Nordisk has filed a lawsuit against Eli Lilly, alleging false advertising and deceptive marketing for Zepbound and Mounjaro treatments.
Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV? FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.
Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings? Eli Lilly has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6.5% to $1,149 p...
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Merck (NYSE:MRK) The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a...
Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table? Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market.
